Sy­ros push­es for a turn­around with new PhII AML re­sults, but in­vestors are unim­pressed

Two years af­ter weak Phase II re­sults cut their stock price in half, Sy­ros Phar­ma­ceu­ti­cals (SYRS) is back with re­sults from an on­go­ing Phase II tri­al try­ing their SY-1425 “su­per-en­hancer” ther­a­py in com­bi­na­tion with chemother­a­py on acute myeloid leukemia (AML) pa­tients. 

It’s ear­ly-stage and the num­bers are small, but of the 13 evalu­able pa­tients who test­ed pos­i­tive for the RARA path­way bio­mark­er Sy­ros’ ther­a­py tar­gets, re­searchers say that 8 had a com­plete re­sponse. That com­pared with 8 com­plete re­spons­es out of 22 pa­tients who didn’t have the gene. The longest CR was 344 days, com­pared with 168 for RARA neg­a­tive pa­tients, al­though Sy­ros not­ed the study is still on­go­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER